[Type 2 diabetes. How can the infarction risk be reduced?].
D020909:Acarbose / Q000008:administration & dosage / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control*; D000077205:Pioglitazone; D012307:Risk Factors; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D045162:Thiazolidinediones; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D020909:Acarbose; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles; D045162:Thiazolidinediones; D014665:Vasodilator Agents
Typ 2 Diabetes. Wie lässt sich das Infarktrisiko reduzieren?